Journal
JOURNAL OF INVESTIGATIVE DERMATOLOGY
Volume 130, Issue 8, Pages 2110-2119Publisher
ELSEVIER SCIENCE INC
DOI: 10.1038/jid.2010.86
Keywords
-
Categories
Funding
- National Institutes of Health [R21-CA 74117, K24-CA 86815]
- Anderson Cancer Center [CA 16672]
- Sherry L. Anderson CTCL Patient Education and Research Fund
Ask authors/readers for more resources
Curcumin inhibits cell growth and induces apoptosis in a number of tumor cell lines and animal models. Human clinical trials indicated no dose-limiting toxicity when administered at doses up to 8 g per day. The purpose of this study was to address the antitumor effect of curcumin on cutaneous T-cell lymphoma (CTCL) cell lines and peripheral blood mononuclear cells (PBMCs) from patients with CTCL compared with healthy donors' controls. Curcumin at 5-20 mu M for 24 and 48 hours induced apoptosis in a time-and dose-dependent manner in three CTCL cell lines (namely MJ, Hut78, and HH). Curcumin at 5-20 mM for 48 hours also caused more apoptosis in patients' PBMCs compared with healthy donors' PBMCs (P<0.05). Curcumin decreased protein and mRNA expression levels of signal transducer and activator of transcription (STAT)-3, bcl-2, and survivin in three cell lines and in patients' PBMCs. Curcumin inhibited STAT-3 and I kappa B-alpha phosphorylation, as well as suppressed DNA binding of nuclear factor (NF)-kappa B in these cells. Caspase-3 was activated and poly (ADP-Ribose) polymerase was cleaved after curcumin treatment. These data suggest that curcumin selectively induces apoptosis in association with the downregulation of STAT-3 and NF-kappa B signaling pathways in CTCL cells. Our findings provide a mechanistic rationale for the potential use of curcumin as a therapeutic agent for patients with CTCL.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available